Angiogenesis: Tumorigenesis and the angiogenic switch
Explore this paper's citation graph
Summary
A more detailed understanding of the complex parameters that govern the interactions between the tumour and vascular compartments will help to improve anti-angiogenic strategies — not only for cancer treatment, but also for preventing recurrence.
- Type
- review
- Published
- 2003-06-01
- Cited by
- 2,070
- References
- 108
- OpenAlex
- https://openalex.org/W2804842145
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11096398
Keywords
Angiogenesis, Carcinogenesis, Stromal cell, Cancer research, Phenotype
References
- Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes
- Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow
- A role for survivin in chemoresistance of endothelial cells mediated by VEGF
- Renal cell carcinoma may adapt to and overcome anti‐angiogenic intervention with thalidomide
- Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.
- Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
- Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis.
- Chemoprevention of Prostate Cancer: Current Status and Future Directions
- Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
- Mechanisms of angiogenesis and arteriogenesis
- Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.
- Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia
- Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
- Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
- Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.
- p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.
- Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
- Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
- Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling.
- Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.
Cited by
- Vascular targeting therapy: potential benefit depends on tumor and host related effects.
- Evaluation of Chloride Intracellular Channels 4 and 1 Functions in Developmental and Pathological Angiogenesis
- Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia.
- Endoscopic imaging of angiogenesis in vivo.
- Antiangiogenesis: biology and utility in the treatment of gliomas
- Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
- Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies
- Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.
- C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC.
- The hemostatic system in angiogenesis.
- Gliomas and the vascular fragility of the blood brain barrier
- Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles.
- hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor
- Dietary weight-loss and exercise effects on serum biomarkers of angiogenesis in overweight postmenopausal women: a randomized controlled trial
- Metronomic chemotherapy and immunotherapy in cancer treatment.
- Construction and expression of a lentivirus expression vector carrying the VEGF165-EGFP fusion gene in breast cancer MCF-7 cells.
- A dose‐escalation study of combretastatin A4‐phosphate in healthy dogs
- Targeting Angiogenesis in Colorectal Carcinoma
- Microvesicles as mediators of intercellular communication in cancer.
- Effect of host age on tumor growth rate in rodents.
Related papers
- The vasohibin family: Novel regulators of angiogenesis.
- The vasohibin family: a novel family for angiogenesis regulation.
- A PlGF-1 Derived Peptide Inhibits Angiogenesis via HIF-1β/VEGF Pathway
- A novel in vitro angiogenesis model based on a microfluidic device
- An endothelium-derived angiogenesis inhibitor vasohibin and its significance in tumor angiogenesis
- Update on endogenous inhibitors of angiogenesis.
- New angiogenesis research
- In Vitro Coculture Assays of Angiogenesis.